JP2023500338A5 - - Google Patents
Info
- Publication number
- JP2023500338A5 JP2023500338A5 JP2022525915A JP2022525915A JP2023500338A5 JP 2023500338 A5 JP2023500338 A5 JP 2023500338A5 JP 2022525915 A JP2022525915 A JP 2022525915A JP 2022525915 A JP2022525915 A JP 2022525915A JP 2023500338 A5 JP2023500338 A5 JP 2023500338A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- pharmaceutical composition
- optionally
- composition according
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962931065P | 2019-11-05 | 2019-11-05 | |
| US62/931,065 | 2019-11-05 | ||
| US201962943627P | 2019-12-04 | 2019-12-04 | |
| US62/943,627 | 2019-12-04 | ||
| PCT/US2020/058788 WO2021091945A1 (en) | 2019-11-05 | 2020-11-04 | Bcma-targeted car-t cell therapy of multiple myeloma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023500338A JP2023500338A (ja) | 2023-01-05 |
| JP2023500338A5 true JP2023500338A5 (https=) | 2024-02-07 |
Family
ID=73598214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525915A Pending JP2023500338A (ja) | 2019-11-05 | 2020-11-04 | 多発性骨髄腫のｂｃｍａを標的としたｃａｒ－ｔ細胞療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12522645B2 (https=) |
| EP (1) | EP4055049A1 (https=) |
| JP (1) | JP2023500338A (https=) |
| KR (1) | KR20220100612A (https=) |
| CN (1) | CN114929747A (https=) |
| AU (1) | AU2020378263A1 (https=) |
| BR (1) | BR112022008633A2 (https=) |
| CA (1) | CA3159808A1 (https=) |
| IL (1) | IL292701A (https=) |
| JO (1) | JOP20220099A1 (https=) |
| MX (1) | MX2022005443A (https=) |
| PH (1) | PH12022551032A1 (https=) |
| WO (1) | WO2021091945A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116096498A (zh) * | 2020-05-04 | 2023-05-09 | 生物诊断有限公司 | 诊断设备 |
| US20240156962A1 (en) * | 2022-11-02 | 2024-05-16 | Legend Biotech Usa Inc. | Bcma-targeted car-t cell therapy of multiple myeloma |
| CN117186229B (zh) * | 2022-12-06 | 2024-03-29 | 成都赛恩吉诺生物科技有限公司 | 具有长cdr3序列的抗人bcma纳米抗体及car-t和应用 |
| CA3205511A1 (en) * | 2023-04-19 | 2025-03-17 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| IE913929A1 (en) | 1990-11-13 | 1992-05-20 | Immunex Corp | Bifunctional selectable fusion genes |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| US20090075378A1 (en) | 2007-02-20 | 2009-03-19 | Anaptysbio, Inc. | Somatic hypermutation systems |
| BR112017007003A2 (pt) | 2014-10-07 | 2017-12-19 | Cellectis | método para modulação de atividade de células imunes induzidas por car |
| WO2018028647A1 (en) | 2016-08-10 | 2018-02-15 | Legend Biotech Usa Inc. | Chimeric antigen receptors targeting bcma and methods of use thereof |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| KR20230148844A (ko) | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| RU2018140056A (ru) | 2016-04-15 | 2020-05-15 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена |
| CN105837693A (zh) | 2016-05-30 | 2016-08-10 | 李斯文 | 一种基于bcma的抗原嵌合受体及其制备方法和应用 |
| WO2021121250A1 (zh) | 2019-12-17 | 2021-06-24 | 深圳市菲鹏生物治疗股份有限公司 | Bcma结合抗体及其用途 |
| WO2022116086A1 (en) | 2020-12-03 | 2022-06-09 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
| KR20240026124A (ko) | 2021-05-11 | 2024-02-27 | 얀센 바이오테크 인코포레이티드 | 키메라 항원 수용체(car) t 세포 요법과 연관된 신경독성을 최소화하는 방법 |
| WO2023077343A1 (en) | 2021-11-04 | 2023-05-11 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
| IL312602A (en) | 2021-11-04 | 2024-07-01 | Janssen Biotech Inc | Bcma-targeted car-t cell therapy for multiple myeloma |
| CA3252674A1 (en) | 2022-02-28 | 2023-08-31 | Nanjing Legend Biotech Co., Ltd. | BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA |
| US20240156962A1 (en) | 2022-11-02 | 2024-05-16 | Legend Biotech Usa Inc. | Bcma-targeted car-t cell therapy of multiple myeloma |
| CA3205511A1 (en) | 2023-04-19 | 2025-03-17 | Janssen Biotech, Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
-
2020
- 2020-11-04 WO PCT/US2020/058788 patent/WO2021091945A1/en not_active Ceased
- 2020-11-04 CN CN202080091870.8A patent/CN114929747A/zh active Pending
- 2020-11-04 US US17/088,845 patent/US12522645B2/en active Active
- 2020-11-04 PH PH1/2022/551032A patent/PH12022551032A1/en unknown
- 2020-11-04 KR KR1020227018771A patent/KR20220100612A/ko active Pending
- 2020-11-04 EP EP20812497.4A patent/EP4055049A1/en active Pending
- 2020-11-04 IL IL292701A patent/IL292701A/en unknown
- 2020-11-04 BR BR112022008633A patent/BR112022008633A2/pt unknown
- 2020-11-04 JP JP2022525915A patent/JP2023500338A/ja active Pending
- 2020-11-04 CA CA3159808A patent/CA3159808A1/en active Pending
- 2020-11-04 AU AU2020378263A patent/AU2020378263A1/en active Pending
- 2020-11-04 MX MX2022005443A patent/MX2022005443A/es unknown
-
2022
- 2022-04-28 JO JOP/2022/0099A patent/JOP20220099A1/ar unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023500338A5 (https=) | ||
| US10766943B2 (en) | Universal chimeric antigen expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| US20190048085A1 (en) | Modified cells for immunotherapy | |
| JP2020529864A (ja) | 多重特異性抗体とその作製及び使用方法 | |
| SG190598A1 (en) | Agent for treating disease | |
| CN110582488A (zh) | 具有增强功效的免疫效应细胞疗法 | |
| JP2020530306A (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP2020530777A (ja) | 多重特異性抗体とその作製及び使用方法 | |
| CN110144012A (zh) | 用于治疗表达紧密连接蛋白的癌症疾病的制剂 | |
| JP7812549B2 (ja) | 人工免疫監視キメラ抗原受容体（ａｉ－ｃａｒ）及びそれを発現する細胞 | |
| KR20180098672A (ko) | 자가-가교결합 항체 | |
| JP2024540275A5 (https=) | ||
| EP4446342A1 (en) | Multi-specific t cell engagers comprising lrrc15 antigen-binding domain | |
| WO2024012457A1 (zh) | 三特异性抗体及其用途 | |
| JP2021501575A (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| JP2021525067A5 (https=) | ||
| CA3158985A1 (en) | Sequential anti-cd19 therapy | |
| EP4566619A1 (en) | Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal | |
| RU2824391C2 (ru) | Иммунные клетки, экспрессирующие обратный универсальный химерный антигенный рецептор, для нацеливания на различные многочисленные антигены и способ их получения и применения для лечения рака, инфекций и аутоиммунных заболеваний | |
| Khan et al. | therapy: antigen selection | |
| Burns | The Major Clinical Components of Cancer Immunotherapy (Modulating Cell-Mediated Immune Mechanisms) | |
| HK40097671A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| HK40097672A (zh) | 制导和导航控制蛋白及其制备和使用方法 | |
| HK40125822A (en) | Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal |